'United Therapeutics' CEO and CFO Realize Share Gains After Exercising Millions in Stock Options

At United Therapeutics Corp. (NASDAQ: UTHR), Chairman and CEO Martin Rosblatt and CFO James Edgemon exercised stock options on May 7 and May 11, 2026, respectively, and sold the resulting common shares in the open market on the same days, realizing gains of over $10 million (approximately KRW 13 billion). Each executive sold exactly the same number of shares as the options exercised, in multiple tranches at an average price of about $570 per share. The company emphasized in its SEC filing that these transactions were conducted under prearranged Rule 10b5-1 trading plans, underscoring the planned nature of the option monetization. Even after these sales, CEO Rosblatt and Mr. Edgemon continue to hold significant economic stakes in the company—directly owning roughly 40,000 and 18,000 shares, respectively, plus additional indirect holdings through family and trust accounts.

In its first-quarter 2026 earnings released on May 6, United Therapeutics reported revenues of approximately $780 million and disclosed positive late-stage clinical data for its pulmonary arterial hypertension therapies ralinepag and inhaled treprostinil. The company subsequently presented additional data at the American Thoracic Society’s ATS 2026 conference. United Therapeutics also announced that the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation for its acute liver failure support device, MiroLiver ELAP, and approved its UHeart xenotransplant clinical trial using pig hearts, demonstrating continued regulatory and clinical momentum across its pipeline. For more information, visit .

Founded in 1996, United Therapeutics is a Nasdaq-listed U.S. biopharmaceutical company focused on treatments for severe cardiopulmonary diseases—such as rare pulmonary arterial hypertension—and on organ regeneration technologies. Founder and current CEO Martin Rosblatt established the company to develop a therapy for his child’s rare disease. In recent years, the company has repeatedly disclosed large stock-based compensation programs alongside planned option exercises and sales by its executives. (Source: )